US FDA declines to approve Milestone's heart rhythm nasal spray; shares halve
Milestone Pharmaceuticals said on Friday the U.S. health regulator had declined to approve its nasal spray to treat a type of ...
abc2715d
Cyrano Therapeutics and Resyca Announce Exclusive License Agreement for Soft Mist Nasal Spray Technology for the Treatment of Chemosensory Dysfunction
Soft Mist Nasal Spray Technology Designed to Enhance Drug Deposition in the Olfactory Region, Increasing the Potential for CYR-064's Therapeutic Efficacy DELRAY BEACH, Fla and ENSCHEDE ...
FDA Rejects Milestone Pharmaceuticals' Etripamil Nasal Spray
The Food and Drug Administration has turned away a proposed nasal spray from Milestone Pharmaceuticals to treat a type of irregular heartbeat over concerns about how the drug is manufactured.
Yahoo Finance15d
Cyrano Therapeutics and Resyca Announce Exclusive License Agreement for Soft Mist Nasal Spray Technology for the Treatment of Chemosensory Dysfunction
Soft Mist Nasal Spray Technology Designed to Enhance Drug Deposition in the Olfactory Region, Increasing the Potential for CYR-064's Therapeutic Efficacy DELRAY BEACH, Fla and ENSCHEDE, Netherlands, ...